Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers September 22, 2017
Pharmacy Choice - Pharmaceutical News - "Crystalline Form of Afatinib Dimaleate" in Patent Application Approval Process (USPTO 20170240533) - September 22, 2017

Pharmacy News Article

 9/14/17 - "Crystalline Form of Afatinib Dimaleate" in Patent Application Approval Process (USPTO 20170240533)

By a News Reporter-Staff News Editor at Politics & Government Week A patent application by the inventors SINGH, Shravan Kumar (Mirzapur, IN); VERMA, Shyam Sunder (Varanasi, IN); SINGH, Kaptan (Gurgaon, IN); PRASAD, Mohan (Gurgaon, IN), filed on October 1, 2015, was made available online on August 31, 2017, according to news reporting originating from Washington, D.C., by VerticalNews correspondents.

This patent application is assigned to Sun Pharmaceutical Industries Limited.

The following quote was obtained by the news editors from the background information supplied by the inventors: "Afatinib dimaleate is a tyrosine kinase inhibitor, chemically designated as 2-butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydro-3-furanyl]oxy] 6-quinazolinyl]-4-(dimethylamino)-,(2E)-, (2Z)-2-butenedioate (1:2) having the structure depicted by Formula I.


"The discovery of new polymorphic forms of a compound is important in the development of pharmaceuticals, as these new forms may result in improved as ease of handling, ease of processing, storage stability, ease of purification, improved dissolution profile, and/or improved shelf-life.

"U.S. Pat. No. 8,426,586 and PCT Publication Nos. WO 2012/121764 and WO 2013/052157 provide processes for the preparation of crystalline forms of afatinib and its salts."

In addition to the background information obtained for this patent application, VerticalNews journalists also obtained the inventors' summary information for this patent application: "The present invention relates to crystalline Form I of afatinib dimaleate, its preparation and pharmaceutical composition thereof, and its use in the treatment of metastatic non-small cell lung cancer.

"The crystalline Form I of afatinib dimaleate of the present invention is highly pure, free-flowing, has good solubility, and prolonged shelf life. It is also stable towards polymorphic conversion and exhibits good bioavailability."

URL and more information on this patent application, see: SINGH, Shravan Kumar; VERMA, Shyam Sunder; SINGH, Kaptan; PRASAD, Mohan. Crystalline Form of Afatinib Dimaleate. Filed October 1, 2015 and posted August 31, 2017. Patent URL:

Keywords for this news article include: Pharmaceutical Companies, Sun Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Sep 24: Using Effective Communication to Reduce Medication Errors
Sep 25: Management of Major Depressive Disorders
Sep 26: Vitamins, Minerals, and Electrolytes in Older Adults
Sep 27: Medication Use During Pregnancy & Lactation
Sep 28: An Integrative Approach to Managing Arthritis
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement